EASTGATE BIOTECH ANNOUNCES THAT ITS RESEARCH COLLABORATOR, THE UNIVERSITY OF GUELPH, DEPARTMENT OF MOLECULAR AND CELLULAR BIOLOGY RECEIVES NSERC GRANT
SALT LAKE CITY, UT and TORONTO, ON--(Marketwired - July _, 2015) - EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced that its research collaborator, the University of Guelph, Department of Molecular and Cellular Biology received a grant from the National Sciences and Engineering Research Council of Canada (NSERC). The grant was approved for the development and evaluation of new nano delivery vehicles for natural antimicrobial products with improved efficacy..
Previously the company announced that its research collaboration with the University of Guelph involved measuring the antimicrobial activity of the company's natural antibacterial products, Cleanezze™ and Vclean™ (www.nano-essentials.com). Cleanezze™ is a long acting hand sanitizer that contains 3 different natural antibacterial compounds. Vclean™ is a natural, non-toxic and highly effective concentrate for the elimination of dangerous germs from surfaces of fruits, vegetables, kitchen tools, etc. The results of this study demonstrated the effectiveness of these products.
The research team at the University of Guelph led by Principal Investigator, Dr. Cezar Khursigara will continue to study the antimicrobial activity of our products.
“We are pleased with the grant awarded to our collaborators at the University of Guelph”, says Anna Gluskin, EastGate's CEO. “This support will serve to validate the effectiveness of the company's natural antibacterial products and provide the competitive benefits for the demanding marketplace looking to combat increases in microbial outbreaks”, continued Ms. Gluskin.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbour" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.
The words "anticipates," "plans," "expects," "indicate," "intend," "scheduled," "estimates," "forecasts," "focus," "guidance," "initiative," "model," "methodology," "outlook," "potential," "projected," "pursue," "strategy," "study," "targets," or "believes," or variations of or similar such words and phrases or statements that certain actions, events or results "may," "could," "would," or "should," "might," or "way forward," "will be taken," "will occur" or "will be achieved" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.